Diagnostic value and clinical significance of anti-GP2 and anti-CUZD1 antibodies in Crohn's disease

doi:10.16150/j.1671-2870.2018.04.015

Abstract

Abstract: Objective: To investigate the diagnostic value and clinical significance of anti-zymogen granule membrane glycoprotein 2 antibody（GP2） and anti-CUB and zonapellucida-like domains-containing protein 1 antibody（CUZD1） in patients with Crohn's disease (CD）. Methods: A total of 128 CD patients, 82 ulcerative colitis (UC) patients and 60 healthy controls were enrolled. Serum anti-GP2 and anti-CUZD1 antibodies were detected by indirect immunofluorescence assay (IIF). Receiver operator characteristic curve (ROC) was used to evaluate the diagnostic efficiency of anti-GP2 and anti-CUZD1 antibodies in single and combining form. The correlation between the two antibodies and clinical characteristics were analyzed by Logistic regression. Results: ① The positive rates of serum anti-GP2 antibodies in CD, UC and health control groups were 45.3%, 11.0%, 0%, respectively. There was significant difference between CD and UC groups（ χ²=27.12, P<0.01）and between CD and health control groups （ χ²=39.32, P<0.01）. Positive rates of serum anti-CUZD1 antibodies in CD, UC and health control groups were 19.5%, 14.6%, 0%, respectively. There was significant difference between CD and health control groups（ χ²=13.52, P<0.01）, but no significant differences was found between CD and UC groups （ χ²=0.83, P=0.36）. ② The sensitivity of anti-GP2 antibodies was 45.3%, the specificity was 93.7% and the area under ROC curve (AUC）was 0.695; the sensitivity of anti-CUZD1 antibodies was 19.5%, the specificity was 91.5% and AUC was 0.555. The diagnostic value of combined anti-GP2 and anti-CUZD1 antibodies was significantly higher than one of them only (Z=4.44, 2.57, respectively, all P<0.01）. ③ Multiple linear regression analysis indicated a positive correlation between anti-GP2 antibody and the perianal, penetrated and ileocolon form of CD（P<0.05）; and anti-CUZD1 antibody was associated with stenosis and terminal ileum form of CD（P<0.05）. Conclusions: Anti-GP2 and anti-CUZD1 antibodies are potential biomarker for the diagnosis of CD. The combination of anti-GP2 and anti-CUZD1 antibodies have higher diagnostic value than one of them only, and could be used to stratify CD patients phenotypically for providing references to establish specific therapeutic strategies.

Key words: Crohn's disease, Zymogen granule membrane glycoprotein, CUB and zonapellucida-like domains-containing protein 1, Immunofluorescence technique, indirect

CLC Number:

R574

ZENG Junxiang, LUO Ting, GE Wensong, PAN Xiujun, SHEN Lisong. Diagnostic value and clinical significance of anti-GP2 and anti-CUZD1 antibodies in Crohn's disease[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 433-438.

References

[1] Ouyang Q, Xue LY.Inflammatory bowel disease in the 21(st) century in China: turning challenges into opportunities[J]. J Dig Dis,2012,13(4):195-199.
[2] Bernstein CN, Eliakim A, Fedail S, et al.World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015[J]. J Clin Gastroenterol,2016,50(10):803-818.
[3] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年·广州)[J]. 中华内科杂志,2012,51(10):818-831.
[4] Pavlidis P, Komorowski L, Teegen B, et al.Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies[J]. Clin Chem Lab Med,2016,54(2):249-256.
[5] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach[J]. Biometrics,1988,44(3):837-845.
[6] Geboes K, De Hertogh G.Indeterminate colitis[J]. Inflamm Bowel Dis,2003,9(5):324-331.
[7] 曾俊祥, 潘秀军, 沈立松. 炎症性肠病血清学标志物的研究进展[J]. 检验医学,2018,33(2):170-176.
[8] Ooi CJ, Fock KM, Makharia GK, et al.The Asia-Pacific consensus on ulcerative colitis[J]. J Gastroenterol Hepatol,2010,25(3):453-468.
[9] 高翔, 胡品津, 郑瑶, 等. 炎症性肠病患者血清中自身抗体检测的临床意义[J]. 中华内科杂志,2005,44(6):428-430.
[10] Deng C, Li W, Li J, et al.Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis[J]. BMJ Open,2017,7(6):e014843.
[11] Farkona S, Soosaipillai A, Filippou P, et al.Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases[J]. Clin Chem Lab Med,2017,55(10):1574-1581.
[12] Komorowski L, Teegen B, Probst C, et al.Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2[J]. J Crohns Colitis,2013,7(10):780-790.
[13] Michaels MA, Jendrek ST, Korf T, et al.Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease[J]. Inflamm Bowel Dis,2015,21(12):2864-2872.
[14] 张鑫, 胡佳, 徐婷, 等. 抗酶原颗粒膜糖蛋白2抗体在炎症性肠病中的临床意义[J]. 中华内科杂志,2014,53(3):214-215.
[15] Papp M, Sipeki N, Tornai T, et al.Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1][J]. J Crohns Colitis,2015,9(8):659-668.
[16] van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety[J]. Am J Gastroenterol,2011,106(9):1594-1602.